Pharvaris B.V. (NASDAQ:PHVS) shares shot up 5.9% on Thursday . The company traded as high as $27.85 and last traded at $27.85. 297 shares traded hands during trading, a decline of 100% from the average session volume of 130,769 shares. The stock had previously closed at $26.31.
Several equities analysts recently commented on PHVS shares. Morgan Stanley restated an “overweight” rating and issued a $51.00 price target on shares of Pharvaris B.V. in a research note on Monday, March 8th. SVB Leerink initiated coverage on shares of Pharvaris B.V. in a research note on Monday, March 8th. They issued an “outperform” rating and a $50.00 price target on the stock. Oppenheimer began coverage on shares of Pharvaris B.V. in a research report on Monday, March 8th. They issued an “outperform” rating and a $48.00 target price on the stock. Finally, Bank of America assumed coverage on shares of Pharvaris B.V. in a report on Monday, March 8th. They set a “neutral” rating and a $41.00 price target for the company.
The company’s 50 day moving average price is $31.51.
Pharvaris B.V., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema. It operates in the Netherlands, Switzerland, and the United States.
Further Reading: Net Income
Receive News & Ratings for Pharvaris B.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharvaris B.V. and related companies with MarketBeat.com's FREE daily email newsletter.